I liked Graham’s comment that the cost of manufacturing the anti-infective product is less than the cost of the bottle that it needs to be stored in.
This has to be a rarity in the pharmaceutical industry, if not unique, and should become a major competitive advantage when financials come into play further down the track.
Ann: Recce to Present at MST Access Investor Conference, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 29.5¢ | 29.0¢ | $38.76K | 133.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 135000 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 15521 | 4 |
View Market Depth
| Last trade - 15.50pm 23/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |